Posts

Posted on

GameStop Provides Corporate Governance Update

Board Has Established New Strategy Committee

GRAPEVINE, Texas, March 08, 2021 (GLOBE NEWSWIRE) — GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today announced that its Board of Directors (the “Board”) has formed a Strategic Planning and Capital Allocation Committee (the “Committee”) to identify initiatives that can further accelerate the Company’s transformation. The Committee is comprised of Alan Attal, Ryan Cohen, and Kurt Wolf, with Mr. Cohen serving as Chairperson. Since the Committee’s formation, the Company has taken steps that include:

  • Appointing a Chief Technology Officer.
  • Hiring two executives to lead the Company’s customer care and e-commerce fulfillment functions, respectively.
  • Appointing Mr. Attal as Chair of the Board’s Nominating and Corporate Governance Committee and Mr. Wolf as Chair of the Board’s Compensation Committee.
  • Announcing a Chief Financial Officer succession plan and commencing a search for a new Chief Financial Officer with relevant technology and/or e-commerce experience.

The Committee will continue to focus on identifying actions that can transform GameStop into a technology business and help create enduring value for stockholders. It is responsible for evaluating areas that include GameStop’s current operational objectives, capital structure and allocation priorities, digital capabilities, organizational footprint, and personnel.


About GameStop

GameStop, a Fortune 500 company headquartered in Grapevine, Texas, is a leading specialty retailer offering games and entertainment products through its e-commerce properties and thousands of stores. Visit www.GameStop.com to explore our products and offerings. Follow @GameStop and @GameStopCorp on Twitter and find us on Facebook at www.facebook.com/GameStop.


Cautionary Statement Regarding Forward-Looking Statements – Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management’s current beliefs, views, estimates and expectations, including as to the Company’s industry, business strategy, goals and expectations concerning its market position, future operations, margins, profitability, comparable store growth, capital expenditures, liquidity, and capital resources and other financial and operating information, including expectations as to future operating profit improvement. Such statements include without limitation those about the Company’s expectations, including as to transformation initiatives and stockholder value, and other statements that are not historical facts. Forward-looking statements are subject to significant risks and uncertainties and actual developments, business decisions, outcomes and results may differ materially from those reflected or described in the forward-looking statements. The following factors, among others, could cause actual developments, business decisions, outcomes and results to differ materially from those reflected or described in the forward-looking statements: macroeconomic pressures, including the effects of COVID-19 on consumer spending and the Company’s ability to keep stores open; the impact of the COVID-19 pandemic on the Company’s business and financial results; the economic conditions in the U.S. and certain international markets; the amounts devoted to strategic investments, including in omni-channel capabilities and other business transformation initiatives, and failure to achieve anticipated profitability increases and benefits from such initiatives within the expected time-frames or at all; the cyclicality of the video game industry; the Company’s dependence on the timely delivery of new and innovative products from its vendors; the impact of technological advances in the video game industry and related changes in consumer behavior on the Company’s sales; the Company’s ability to keep pace with changing industry technology and consumer preferences; decrease in popularity of certain types of video games; the Company’s ability to react to trends in pop culture with regard to its sales of collectibles and dependence on licensed products for a substantial portion of such sales; the competitive nature of the Company’s industry, including competition from omni-channel retailers, e-commerce businesses, and traditional store-based retailers; the ability and willingness of the Company’s vendors to provide marketing and merchandise support at historical or anticipated levels; the Company’s ability to attract and retain executive officers, including a new chief financial officer, and other key personnel; the Company’s ability to obtain favorable terms from its suppliers; the international nature of the Company’s business; foreign currency fluctuations; changes in the Company’s global tax rate; the impact of international crises and trade restrictions and tariffs on the delivery of the Company’s products; the Company’s dependence on sales during the holiday selling season; fluctuations in the Company’s results of operations from quarter to quarter; the Company’s ability to de-densify its global store base; the Company’s ability to renew, terminate or enter into new leases on favorable terms; the adequacy of the Company’s management information systems; the Company’s reliance on centralized facilities for refurbishment of its pre-owned products; the Company’s ability to maintain security of its customer, employee or company information; potential harm to the Company’s reputation, including from cybersecurity breaches; the Company’s ability to maintain effective control over financial reporting; restrictions on the Company’s ability to purchase and sell pre-owned video games; potential future litigation and other legal proceedings; changes in accounting rules and regulations; and the Company’s ability to comply with federal, state, local and international law. Additional factors that could cause results to differ materially from those reflected or described in the forward-looking statements can be found in Exhibit 99.4 of GameStop’s Current Report on Form 8-K filed on June 5, 2020 and in GameStop’s Quarterly report on Form 10-Q filed on September 9, 2020 and other filings made from time to time with the SEC and available at the SEC’s Internet site at http://www.sec.gov or http://investor.GameStop.com. Forward-looking statements contained in this release speak only as of the date of this release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.


Contacts

For investors:
GameStop Investor Relations
817-424-2001
[email protected]

For media:
GameStop Public Relations
Joey Mooring
[email protected]

or

Profile
Greg Marose / Charlotte Kiaie
[email protected]

 



Posted on

CytRx Highlights Orphazyme’s Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

CytRx Highlights Orphazyme’s Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

Orphazyme Announces the Global Brand Name for Arimoclomol – MIPLYFFA – Ahead of Prospective FDA and EMA Approvals

Expanded its Early Access Program for NPC in the U.S. and Europe as Well as Expectation of European Regulatory Decision by Q4 2021

LOS ANGELES–(BUSINESS WIRE)–
CytRx Corporation (OTCQB: CYTR) (“CytRx”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (NASDAQ: ORPH) (“Orphazyme”) has released a new investor presentation that outlines its momentum ahead of potential U.S. and European approval of arimoclomol for the treatment of Niemann-Pick disease Type C (“NPC”). The March 2nd presentation can be found under the “Events & Presentations” section of www.orphazyme.com. CytRx has an agreement with Orphazyme that can yield potential milestone payments and future single and double-digit royalties paid on sales of arimoclomol.

Items noted in the presentation include:

  • Arimoclomol expected to be first to market in NPC in the U.S.
  • In anticipation of U.S. Food and Drug Administration (“FDA”) and European Medicine Agency (“EMA”) approval, Orphazyme announced MIPLYFFA as the global brand name for arimoclomol.
  • Orphazyme has expanded its NPC Early Access Program (EAP) in the U.S. and opened similar programs in France and Germany.
  • Orphazyme now expects to receive a decision on European regulatory approval for arimoclomol for NPC by Q4 2021.
  • Arimoclomol for NPC remains under the FDA’s priority review with a Prescription Drug User Fee Act target action date of June 17, 2021.
  • Orphazyme has expanded its commercial organization in the U.S. and EU while extending its footprint to support launch readiness.
  • Goal is to position arimoclomol as first-line in NPC globally.
  • Orphazyme projects arimoclomol sales for NPC this year of up to $20 million.

Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, commented:

“We are very excited to see Orphazyme announce a global brand name for arimoclomol ahead of potential regulatory approvals in the U.S. and Europe. We are equally enthusiastic about the company’s commitment to expanding EAPs and fortifying its global operations in anticipation of commercializing MIPLYFFA. In our view, Orphazyme is taking the right steps to commence future distribution and enhance its engagement with providers, patients and regulators. CytRx looks forward to monitoring Orphazyme’s progress as it works to make MIPLYFFA available for NPC and three other rare diseases over time.”

We will continue to provide updates that are relevant to our agreement with Orphazyme. As noted, Orphazyme’s March 2nd presentation can be found under the “Events & Presentations” section of www.orphazyme.com.

About CytRx Corporation

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S (Nasdaq Copenhagen exchange: ORPHA.CO) in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in four indications including Amyotrophic Lateral Sclerosis (“ALS”), Niemann-Pick disease Type C (“NPC”), Gaucher disease and Inclusion Body Myositis (“IBM”). Learn more at www.cytrx.com.

About Orphazyme

Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life threatening or debilitating rare diseases. Their research focuses on developing therapies for diseases caused by misfolding of proteins including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme shares are listed on Nasdaq (ORPH). For more information, please visit www.orphazyme.com.

About NPC

Niemann-Pick disease Type C (NPC) is a rare, genetic and progressive disease that impairs the ability of the body to move cholesterol and other fatty substances (lipids) inside the cells. The result is an accumulation of lipids within the body’s tissue, including the brain tissue, causing damage to the affected 2 areas. The symptoms upon onset of NPC vary from fatality during the first months after birth to a progressive disorder not diagnosed until adulthood. The disease affects neurologic and psychiatric functions as well as various internal organs. Systemic symptoms of NPC are more common in infancy or childhood and the rate of progression is usually much slower in individuals with onset of symptoms during adulthood. NPC is usually fatal and the majority of individuals with the disease die before the age of 20. NPC has been granted Orphan Drug Designation (EU and U.S.) for the treatment of NPC. It is estimated the incidence of NPC to be one in 100,000 live births and the number of NPC patients in the United States and in Europe to be approximately 1,800 individuals. There are no approved treatments for NPC in the U.S. and only one approved product in Europe called miglustat.

About Arimoclomol

Arimoclomol is an investigational drug candidate that amplifies the production of heat-shock proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally, crosses the blood brain barrier, and has been studied in seven Phase 1, four Phase 2 and one pivotal Phase 2/3 clinical trial. Arimoclomol is in clinical development at Orphazyme for the treatment of NPC, Gaucher disease, IBM and ALS. Arimoclomol has received orphan drug designation for NPC, IBM and ALS in the US and EU, as well as fast-track designation from the US Food and Drug Administration (FDA) for NPC, IBM and ALS. In addition, arimoclomol has received breakthrough therapy designation and rare-pediatric disease designation from the FDA for NPC.

Forward-Looking Statements

This press release contains forward-looking statements, including statements relating to the potential receipt of EMA and FDA approval of arimoclomol, the Company’s potential receipt of future milestone and royalty payments from Orphazyme and the achievement of long-term value for the Company’s stockholders. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to the ability of Orphazyme to obtain regulatory approval for, manufacture and commercialize its products and therapies that use arimoclomol; the results of clinical trials involving arimoclomol; the amount, if any, of future milestone and royalty payments that we may receive from Orphazyme; and other risks and uncertainties described in the most recent annual and quarterly reports filed by the Company with the SEC and current reports filed since the date of the Company’s most recent annual report. All forward-looking statements are based upon information available to the Company on the date the statements are first published. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For Investors:

Greg Marose / Bela Kirpalani

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Oncology FDA Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Posted on

Gibson Energy Recognized as Sustainability Leader and Announces Establishment of Expanded Sustainability and ESG Targets

CALGARY, Alberta, March 08, 2021 (GLOBE NEWSWIRE) — Gibson Energy Inc. is pleased to announce today the establishment of expanded Sustainability and Environmental, Social and Governance (“ESG”) targets as well as its intention to publish reporting during the year aligned to both the Task Force on Climate Related Financial Disclosure (“TCFD”) and the Sustainability Accounting Standards Board (“SASB”) frameworks, building on its industry leading ESG ratings from several globally recognized ratings agencies.

“Gibson strongly believes in the importance of engraining Sustainability and ESG principles throughout all parts of the organization in order to best position the Company for success over the long-term,” said Steve Spaulding, President and Chief Executive Officer. “The core principles of Sustainability and ESG have been a part of Gibson for a very long time as reflected by our current rankings from third-party ESG ratings agencies, however, over the past year we began placing increased focus on evolving our sustainability practices and improving our disclosure and transparency. Today, by setting out relevant, measurable targets, we are taking the next step as we continue to do our part in addressing global environmental and social challenges and remain a leader for positive change within our industry.”

ESG Targets

Gibson’s overarching goal is to be a Sustainability and ESG leader relative to its peers. In charting its sustainability journey, Gibson performed comprehensive materiality assessments utilizing applicable factors set out by TCFD and SASB in order to create a framework reflective of the key issues for its sector while focusing on the issues with the most potential to impact the Company’s operations.

      Key Target   Key Target
Category   Metric   Year   Metric   Year
GHG Emissions

(1)
 		               
  GHG Overall Intensity Reduction   15
% 		  2025   20
% 		  2030
  GHG Processing Intensity Reduction   30
% 		  2025   40
% 		  2030
  GHG Storage and Handling Intensity Reduction   60
% 		  2025   95
% 		  2030
  Scope 2 Absolute Emissions Reduction   50
% 		  2025   100
% 		  2030
  MJF Scope 1 and 2 Emissions Absolute Reduction   15
% 		  2025        
Diversity and Inclusion                
  Women in the Workforce   40 – 42%   2025   43 – 45%   2030
  Women Vice Presidents and Above   33 – 40%   2025   40 – 45%   2030
  Women Senior Vice Presidents or Above   At least 1   2025        
  Racial and Ethnic Minority Representation   21 – 23%   2025   23 – 25%   2030
  Indigenous Representation   2.5 – 3.0%   2025   3.5 – 4.0%   2030
  Racial and Ethnic Minority and/or Indigenous Senior Vice Presidents or Above   At least 1   2025        
  Women Board Representation   40
% 		  2025        
  Racial and Ethnic Board Representation   At least 1   2025        
Community                
  Community Giving Initiatives   $5mm   Thru 2025        
  Workforce Participation In Giving   80%   Thru 2025        
                   
Health and Safety Achieve and Maintain Top Quartile
  
                   
Sustainability Leadership   Remain Top Quartile    
Note: All targets are established on a 2020 baseline.

(1) Intensity targets include scope 1 and 2 emissions only. 		               

“Through benchmarking our business against TCFD and SASB standards, and in consultation with our stakeholders, we identified and prioritized our ESG framework,” said Judy Cotte, Director and Chair of the Sustainability and ESG Board Committee. “Within the traditional pillars of ESG, Gibson has identified GHG emissions, diversity and inclusion, health and safety and community impact as our most immediate focus areas. In each of these areas, we have set aspirations with interim milestones to ensure accountability to these targets and build upon our leadership position.”

“While we, along with the rest of the Canadian energy industry, are already operating within one of the most robust ESG regulatory frameworks in the world, taking this decisive action through the setting of targets, including interim milestones to achieve those targets, will help accelerate our efforts within each of these purpose-driven areas of focus,” said Sean Wilson, Gibson’s Senior Vice President, Chief Administrative Officer and Sustainability Lead. “Through our efforts over the past year, including publishing our inaugural Sustainability Report and receiving an A- on our inaugural CDP submission, we have laid a strong foundation for our ESG journey. With the targets we have established today, and in our future disclosure which will track our progress against those targets, we are ensuring we will maintain and grow our leadership position in Sustainability and ESG.”

GHG Emissions

While the Company believes it already has one of the lowest GHG emissions footprints within the Canadian energy infrastructure space, recognizing the importance of global actions to address GHG emissions, Gibson will reduce its GHG intensity across all its business units in 2025 and 2030. By 2030, Gibson’s overall intensity will reduce by 20%, its processing intensity will reduce by 40% and its storage and handling intensity will reduce by 95% as compared to a 2020 baseline. Supporting this goal, the Company will reduce its absolute scope 1 and scope 2 emissions at the Moose Jaw Facility by 15% by 2025 and fully eliminate its absolute scope 2 impact from its entire business by 2030.

Gibson has already made meaningful progress in reducing its GHG emissions, including its recent investment in thermal heat exchanger technology at the Moose Jaw Facility as part of the recent $20 million expansion, resulting in an anticipated reduced emissions intensity of nearly 20-25%. Continuing its focus on improving the emissions profile of the Moose Jaw Facility, the Company has also allocated capital within its 2021 budget to further reduce emissions intensity by switching from a feedstock-based fuel supply to natural gas.

Gibson already considers the impact of GHG emissions as part of its capital review processes and has formed internal teams to identify and advance incremental opportunities for the reduction of GHG emissions. The Company considers innovation and optimization as being key to unlocking additional GHG reduction opportunities and remains committed to ensuring that all of its capital investments continue to realize the Company’s internal return hurdles.

Additionally, as part of its focus on GHG emissions, the Company is in the process of finalizing the quantification and verification of the Company’s remaining scope 3 categories as well as the GHG emissions from its U.S. operations in order to enable it to provide full emissions disclosure for the Company. Also, building on disclosures contained in the Company’s inaugural CDP Climate Change submission, the Company intends to complete the 2021 CDP Climate Change questionnaire. The Company also expects to release a Sustainability Report update during the year which will be aligned to both TCFD and SASB and include an update of key metrics set out in the Company’s inaugural Sustainability Report released in 2020.

Diversity and Inclusion

Gibson believes that a diverse and inclusive organization, which seeks to engage the broadest range of people and ideas, is integral to creating a high-performance organization and driving innovation. To access these benefits, Gibson will seek to shape an organization where women comprise 43% to 45% of the workforce by 2030, including 40% to 45% within vice president and above roles, while targeting 23% to 25% racial and ethnic minority representation and 3.5% to 4.0% Indigenous representation by 2030. Gibson has also set diversity targets at the highest level in the organization and by 2025, the Company’s senior vice presidents or above will include at least one woman as well as at least one person who identifies as a racial and ethnic minority and/or Indigenous Persons.

At the Board level, Gibson’s Board of Directors will achieve and maintain a Board composition of at least 40% women directors, including at least one director that identifies as a racial and ethnic minority and/or Indigenous Persons by 2025. Also, in support of its diversity and inclusion goals, the Company has expanded its Diversity and Inclusion Policy to include racial and ethnic minorities as well as Indigenous Persons and incorporated the diversity targets mentioned above. The Company has also implemented a Labour & Human Rights Policy and Shareholder Engagement Policy.

Community

Reflective of the belief that companies need to support the communities in which they operate in and around, Gibson will contribute at least $5 million dollars to community giving initiatives through 2025, with an annual minimum of $1 million. This commitment builds on the five-year, $1 million partnership that Gibson recently announced with Trellis (formerly the Boys & Girls Clubs of Calgary and Aspen Family & Community Network Society) to provide mental health support to youth, the largest contribution in the Company’s history. In addition to its corporate financial support, and in order to ensure that its employees engage with their local communities, Gibson will strive to maintain average workforce community giving and/or participation of at least 80% through to 2025.

Health and Safety

In 2020, as part of its perpetual focus on employee health and safety, Gibson launched its Mission Zero Program to drive continued improvement, with Total Recordable Injury Frequency (“TRIF”) identified as one of the key metrics. By 2025, Gibson will target top quartile performance among its peer group, with the ultimate aspirational goal always being zero harm to people, the environment and assets. In the interim, in 2021, Gibson aims to achieve a TRIF of 0.5 incidents (or less) per 200,000 employee-hours which currently equates to top-quartile performance.

Additional information on Gibson’s approach to Sustainability and ESG, is available at: https://www.gibsonenergy.com/our-responsibility/sustainability/

Current ESG Benchmarking

The following table summarizes Gibson’s Sustainability and ESG progress, as provided by several globally recognized rating agencies:

Rating Agency   Score / Ranking   Description of Ranking
         
CDP – Climate Change   A-   Top 10% globally within industry group

A- on supplier engagement

Gibson was one of 7 oil and gas companies throughout North America to receive this distinction
         
         
Sustainalytics ESG Rating
(Refiners and Pipelines)		   9 out of 195   Top 5% within industry group
         
         
MSCI ESG Risk Ratings   A   Measurement of resilience to long-term, industry material environmental, social and governance risks on a relative ranking from AAA being the best to CCC being the worst
         
         
ISS Governance Quality Score   1   Denotes decile ranking score on a scale of 1 being the best to 10 being the worst, with a score of 1 indicating top 10% performance within Energy industry group
       
ISS Environmental Quality Score   3  
       
ISS Social Quality Score   3  

About Gibson

Gibson Energy Inc. (“Gibson” or the “Company”), (TSX: GEI) is a Canadian-based oil infrastructure company with its principal businesses consisting of the storage, optimization, processing, and gathering of crude oil and refined products.  Headquartered in Calgary, Alberta, the Company’s operations are focused around its core terminal assets located at Hardisty and Edmonton, Alberta, and also include the Moose Jaw Facility and an infrastructure position in the U.S.

Gibson shares trade under the symbol GEI and are listed on the Toronto Stock Exchange. For more information, visit www.gibsonenergy.com. 

Forward-Looking Statements

Certain statements contained in this news release constitute forward-looking information and statements (collectively, “forward-looking statements”) including, but not limited to, statements related to Gibson’s business; anticipated GHG emission reductions; sustainability and ESG initiatives, priorities, targets, and anticipated disclosure and reporting; the review and amendments to Gibson’s governance policies; Gibson’s anticipated charitable actions; Gibson’s continued position as an ESG industry leader; Gibson’s diversity targets for employees, officers, and board members; and related matters. All statements other than statements of historical fact are forward-looking statements. The use of any of the words ‘‘anticipate’’, “achieve”, “seek”, ‘‘plan’’, ‘‘continue’’, ‘‘estimate’’, ‘‘expect’’, ‘‘intend’’, , ‘‘may’’, ‘‘will’’, ‘‘shall’’, ‘‘project’’, ‘‘should’’, ‘‘could’’, ‘‘would’’, ‘‘believe’’, ‘‘predict’’, ‘‘potential’’, “prioritize”, “goal”, “focus”, “remain”, and “target” and similar expressions are intended to identify forward looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In addition, this news release may contain forward-looking statements and forward-looking information attributed to third party industry sources. The Company does not undertake any obligations to publicly update or revise any forward-looking statements except as required by securities law. Actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous risks and uncertainties including, but not limited to, the risks and uncertainties described in “Forward-Looking Statements” and “Risk Factors” included in the Company’s Annual Information Form dated February 24, 2020 as filed on SEDAR and available on the Gibson website at www.gibsonenergy.com.

For further information, please contact:

Investor Relations:

Mark Chyc-Cies
Vice President, Strategy, Planning & Investor Relations
Phone: (403) 776-3146
Email: [email protected]

Sustainability:

Sean Wilson
Senior Vice President, Chief Administrative Officer and Sustainability Lead
Phone: (403) 206-4132
Email: [email protected]

Media:

Wendy Robinson
Director, Communications & Brand
Phone: (403) 827-6057
Email: [email protected]

 



Posted on

NextDecade and Bechtel Complete Pricing Refresh on EPC Agreements

NextDecade and Bechtel Complete Pricing Refresh on EPC Agreements

HOUSTON–(BUSINESS WIRE)–
NextDecade Corporation (NextDecade or the Company) (NASDAQ: NEXT) and Bechtel Oil, Gas, and Chemicals, Inc. (Bechtel) have completed a pricing refresh on the fully wrapped lump-sum turnkey (LSTK) engineering, procurement, and construction agreements for the first three trains at NextDecade’s Rio Grande LNG project (EPC Agreements) resulting in no impact to the overall cost of the project. The pricing in the EPC Agreements is now valid until December 31, 2021. Additionally, NextDecade and Bechtel agreed to extend the validity of the EPC Agreements until July 31, 2022.

“We value our strong partnership with Bechtel, the world’s leading LNG EPC contractor,” said Matt Schatzman, NextDecade’s Chairman and Chief Executive Officer. “Our global LNG customers, feed gas suppliers, and other stakeholders can have the utmost confidence in the on-time and on-budget delivery of our Rio Grande LNG project. We are pleased to continue to progress our engineering and procurement activities under limited notices to proceed, and we look forward to providing Bechtel with a full notice to proceed with the development of this world-class project immediately following FID.”

NextDecade anticipates achieving a final investment decision on a minimum of two trains at Rio Grande LNG in 2021.

About NextDecade Corporation

NextDecade Corporation (NextDecade) is a liquefied natural gas (LNG) company focused on delivering the 27 mtpa Rio Grande LNG export facility in South Texas. Rio Grande LNG will be the largest U.S. LNG export solution linking Permian Basin and Eagle Ford Shale natural gas to the global LNG market. Utilizing carbon capture and storage technology and proprietary processes, NextDecade is targeting carbon neutrality at Rio Grande LNG. NextDecade’s common stock is listed on the Nasdaq Stock Market under the symbol “NEXT.” NextDecade is headquartered in Houston, Texas. For more information, visit www.next-decade.com.

NextDecade Forward-Looking Information

This press release contains forward-looking statements within the meaning of U.S. federal securities laws. The words “anticipate,” “contemplate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “might,” “will,” “would,” “could,” “should,” “can have,” “likely,” “continue,” “design” and other words and terms of similar expressions are intended to identify forward-looking statements, and these statements may relate to the business of NextDecade and its subsidiaries. These statements have been based on NextDecade’s current assumptions, expectations, and projections about future events and trends and involve a number of known and unknown risks, which may cause actual results to differ materially from expectations expressed or implied in the forward-looking statements. These risks include uncertainties about progress in the development of NextDecade’s LNG liquefaction and export projects and the timing of that progress; NextDecade’s final investment decision (“FID”) in the construction and operation of a LNG terminal at the Port of Brownsville in southern Texas (the “Terminal”) and the timing of that decision; the successful completion of the Terminal by third-party contractors and an approximately 137-mile pipeline to supply gas to the Terminal being developed by a third-party; NextDecade’s ability to secure additional debt and equity financing in the future to complete the Terminal; the accuracy of estimated costs for the Terminal; statements that the Terminal, when completed, will have certain characteristics, including amounts of liquefaction capacities; the development risks, operational hazards, regulatory approvals applicable to the Terminal’s and the third-party pipeline’s construction and operations activities; NextDecade’s anticipated competitive advantage and technological innovation which may render its anticipated competitive advantage obsolete; the global demand for and price of natural gas (versus the price of imported LNG); the availability of LNG vessels worldwide; changes in legislation and regulations relating to the LNG industry, including environmental laws and regulations that impose significant compliance costs and liabilities; the 2019 novel coronavirus pandemic and its impact on NextDecade’s business and operating results, including any disruptions in NextDecade’s operations or development of the Terminal and the health and safety of NextDecade’s employees, and on NextDecade’s customers, the global economy and the demand for LNG; risks related to doing business in and having counterparties in foreign countries; NextDecade’s ability to maintain the listing of its securities on a securities exchange or quotation medium; changes adversely affecting the business in which NextDecade is engaged; management of growth; general economic conditions; NextDecade’s ability to generate cash; compliance with environmental laws and regulations; the result of future financing efforts and applications for customary tax incentives; and other matters discussed in the “Risk Factors” section of NextDecade’s Annual Report on Form 10-K for the year ended December 31, 2019 and other subsequent reports filed with the Securities and Exchange Commission, all of which are incorporated herein by reference.

Additionally, any development of the Terminal remains contingent upon completing required commercial agreements, acquiring all necessary permits and approval, securing all financing commitments and potential tax incentives, achieving other customary conditions and making a final investment decision to proceed. The forward-looking statements in this press release speak as of the date of this release. Although NextDecade believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that the expectations will prove to be correct. NextDecade may from time to time voluntarily update its prior forward-looking statements, however, it disclaims any commitment to do so except as required by securities laws.

Patrick Hughes

[email protected]

+1 (832) 209-8131

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Energy Other Energy Environment Oil/Gas

MEDIA:

Logo
Logo
Posted on

Mojave Announces Amended Financing

VANCOUVER, British Columbia, March 08, 2021 (GLOBE NEWSWIRE) — Mojave Gold Corp. (“Mojave” or the “Company”) (TSXV: MOJ) is pleased to announce its intention to undertake a non-brokered private placement of up to 6,000,000 units of the Company (the “Units”) at a price of $0.50 per Unit (the “Offering”) for a total of CA $3.0 million.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one purchase warrant (each whole warrant, a “Warrant”). Each Warrant is exercisable to acquire one Common Share (a “Warrant Share”) at a price of $0.88 per Warrant Share for a period of 36 months from the date the financing is closed.

Finder’s fees may be payable to qualified individuals comprised of shares, warrants or cash or any combination thereof.

The Offering will be conducted pursuant to available prospectus exemptions including sales to accredited investors, family members, close friends and business associates of directors and officers of the Corporation, to purchasers who have obtained suitability advice from a registered investment dealer pursuant to the exemption set out in BC Instrument 45-536 (Exemption from prospectus requirement for certain distributions through an investment dealer) (the “Investment Dealer Exemption”) and to existing shareholders of the Corporation pursuant to the exemption set out in British Columbia Securities Commission BC Instrument 45- 534 (Exemption from prospectus requirement for certain trades to existing security holders) (the “Existing Shareholder Exemption”).   

For subscribers utilizing the Existing Shareholder Exemption, the Offering is available to all shareholders of the Company as at March 8, 2021, (the “Record Date”) (and still are shareholders) who are eligible to participate under the Existing Shareholder Exemption. Any person who becomes a shareholder of the Company after the Record Date is not permitted to participate in the offerings using the Existing Shareholder Exemption but other exemptions may still be available to them. Shareholders who became shareholders after the record date should consult their professional advisors when completing their subscription form to ensure that they use the correct exemption.

There are conditions and restrictions when relying upon the Existing Shareholder Exemption, namely, the subscriber must: a) be a shareholder of the Company on the Record Date (and still are a shareholder), b) be purchasing the Units as a principal, i.e. for their own account and not for any other party, and c) may not purchase more than $15,000 value of securities from the Company in any twelve month period, unless they have first received ‘suitability advice’ from a registered investment dealer and, in this case, subscribers will be asked to confirm the registered investment dealer’s identity and employer.

The proposed net proceeds received from the Offering after payment of commissions are intended to be used by the Company to pay expenses related to the Company’s properties under option agreement in Mexico, settle payables and for working capital the following purposes:

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Mojave Gold Corp.: Media Snippet.

While the Company intends to spend the net proceeds from the Offering as stated above, there may be circumstances where, for sound business reasons, funds may be reallocated at the discretion of the Board.

Subscribers in all Canadian jurisdictions may utilize the Existing Shareholder Exemption. Existing shareholders resident in countries other than Canada will need to meet local jurisdiction requirements to participate.

Subscribers implementing the Investor Dealer Exemption must reside in one of the following jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick and Saskatchewan. Subscribers resident in countries other than Canada will need to meet local jurisdiction requirements to participate.

The Company announces that it will not be proceeding with the private placement as previously announced on February 24, 2021.

On behalf of the Board of Directors

“Cole McClay”, CEO Mojave Gold Corp.

[email protected]

www.mojavegoldcorp.com

Forward Looking Statements

Certain of the statements made and information contained herein may contain forward- looking information within the meaning of applicable Canadian securities laws. Forward-looking information includes, but is not limited to, information concerning the Company’s intentions with respect to the development of its mineral properties. Forward-looking information is based on the views, opinions, intentions and estimates of management at the date the information is made, and is based on a number of assumptions and subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated or projected in the forward-looking information (including the actions of other parties who have agreed to do certain things and the approval of certain regulatory bodies). Many of these assumptions are based on factors and events that are not within the control of the Company and there is no assurance they will prove to be correct. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by applicable securities laws, or to comment on analyses, expectations or statements made by third parties in respect of the Company, its financial or operating results or its securities. The reader is cautioned not to place undue reliance on forward-looking information. We seek safe harbour. 



Posted on

Headstrong Project Inc. Announces Partnership with Wounded Warrior Project to Increase Mental Health Service Innovations for Veterans and Their Families

New York, NY, March 08, 2021 (GLOBE NEWSWIRE) — Headstrong Project Inc., a national mental health treatment practice providing veterans with barrier-free mental health care, received a grant from Wounded Warrior Project® (WWP) to increase mental health treatment innovations. Amid ongoing efforts to meet the growing demand for critical mental health access for the nation’s veteran families, the funding will help Headstrong expand its program delivery model, enabling it to quickly respond to veterans’ needs surrounding isolation, depression, and anxiety – the hallmarks of quarantine during the pandemic. 

“Based on the WWP Annual Warrior Survey of wounded veterans we serve, amid the COVID-19 pandemic, three in five (61%) say they feel more disconnected from my family, friends, or community,” said Michael Richardson, WWP Vice President of Independence Services and Mental Health. “Community and connection are critical to the health and wellness of the warriors we serve. We’re proud to support Headstrong Project in its efforts to provide resources and care for warriors and family members struggling with isolation, anxiety, and loneliness.” 

Working in partnership with Weill Cornell Medical College, one of the nation’s leading mental health care centers, Headstrong developed a first-of-its-kind program tailored to each individual’s needs. The customized treatments address post-traumatic stress disorder (PTSD), addiction, anxiety and depression, trauma, grief, and anger management. Grant funding will help expand telehealth treatment capacity in strategic market areas, especially for warriors located in rural markets and where barriers imposed by the pandemic limit access to mental healthcare. 

“Our partnership with the Wounded Warrior Project couldn’t have come at a more important time in Headstrong’s history,” said COL (U.S. Army, Ret.) Jim McDonough, Headstrong’s Executive Director.  “In the middle of a raging global public health crisis that continues to adversely impact our nation’s wounded warriors and their families, Headstrong has delivered uninterrupted care and treatment, thanks in large part to the support provided by organizations like the Wounded Warrior Project.”

WWP’s investment will expand access to world-class clinicians and broaden the overall value of Headstrong’s services by:

  • Provide 2,400 therapy sessions through Headstrong’s hybrid-model (telehealth and in-person services).
  • Expanding partnerships with trusted veteran service organizations and insurance administrators to generate increased referrals. The funding will also help sustain a world-class network of 250 clinicians nationwide. 

Headstrong has demonstrated success in eliminating, or significantly decreasing, symptoms of mental health challenges and creating positive results such as: 53% of clients reporting improved sleep, 73% of clients reporting improved relationships, and 74% of clients reporting decrease in drug use. Since its inception in 2012, Headstrong has served nearly 1,800 clients every month, through thousands of clinical care sessions delivered by world-class, trauma-informed therapists, leading to improvements in mental health within the post-9/11 veteran population. To learn more, visit getheadstrong.org. 

About Headstrong
Founded in 2012, Headstrong provides confidential, cost-free and bureaucracy-free mental health care treatment for military veterans and their families. Headstrong currently offers effective, individually tailored and comprehensive in-person and telehealth treatment programs for Post-Traumatic Stress Disorder and other related military trauma within 12 States and 28 markets. Treating ~1,800 veterans with over 68,000 clinical sessions, Headstrong is well on its way to become the National mental health treatment practice of choice for America’s military connected families. Follow Headstrong @getheadstrong on social media or visit our website: getheadstrong.org to learn more on how Headstrong is healing the hidden wounds of war.

 

About Wounded Warrior Project
Since 2003, Wounded Warrior Project® (WWP) has been meeting the growing needs of warriors, their families, and caregivers — helping them achieve their highest ambition. Learn more. 

Attachment 



Lora Dircz
The Headstrong Project
702-400-7037
[email protected]

Posted on

NextDecade and Bechtel Complete Pricing Refresh on EPC Agreements

NextDecade and Bechtel Complete Pricing Refresh on EPC Agreements

HOUSTON–(BUSINESS WIRE)–
NextDecade Corporation (NextDecade or the Company) (NASDAQ: NEXT) and Bechtel Oil, Gas, and Chemicals, Inc. (Bechtel) have completed a pricing refresh on the fully wrapped lump-sum turnkey (LSTK) engineering, procurement, and construction agreements for the first three trains at NextDecade’s Rio Grande LNG project (EPC Agreements) resulting in no impact to the overall cost of the project. The pricing in the EPC Agreements is now valid until December 31, 2021. Additionally, NextDecade and Bechtel agreed to extend the validity of the EPC Agreements until July 31, 2022.

“We value our strong partnership with Bechtel, the world’s leading LNG EPC contractor,” said Matt Schatzman, NextDecade’s Chairman and Chief Executive Officer. “Our global LNG customers, feed gas suppliers, and other stakeholders can have the utmost confidence in the on-time and on-budget delivery of our Rio Grande LNG project. We are pleased to continue to progress our engineering and procurement activities under limited notices to proceed, and we look forward to providing Bechtel with a full notice to proceed with the development of this world-class project immediately following FID.”

NextDecade anticipates achieving a final investment decision on a minimum of two trains at Rio Grande LNG in 2021.

About NextDecade Corporation

NextDecade Corporation (NextDecade) is a liquefied natural gas (LNG) company focused on delivering the 27 mtpa Rio Grande LNG export facility in South Texas. Rio Grande LNG will be the largest U.S. LNG export solution linking Permian Basin and Eagle Ford Shale natural gas to the global LNG market. Utilizing carbon capture and storage technology and proprietary processes, NextDecade is targeting carbon neutrality at Rio Grande LNG. NextDecade’s common stock is listed on the Nasdaq Stock Market under the symbol “NEXT.” NextDecade is headquartered in Houston, Texas. For more information, visit www.next-decade.com.

NextDecade Forward-Looking Information

This press release contains forward-looking statements within the meaning of U.S. federal securities laws. The words “anticipate,” “contemplate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “might,” “will,” “would,” “could,” “should,” “can have,” “likely,” “continue,” “design” and other words and terms of similar expressions are intended to identify forward-looking statements, and these statements may relate to the business of NextDecade and its subsidiaries. These statements have been based on NextDecade’s current assumptions, expectations, and projections about future events and trends and involve a number of known and unknown risks, which may cause actual results to differ materially from expectations expressed or implied in the forward-looking statements. These risks include uncertainties about progress in the development of NextDecade’s LNG liquefaction and export projects and the timing of that progress; NextDecade’s final investment decision (“FID”) in the construction and operation of a LNG terminal at the Port of Brownsville in southern Texas (the “Terminal”) and the timing of that decision; the successful completion of the Terminal by third-party contractors and an approximately 137-mile pipeline to supply gas to the Terminal being developed by a third-party; NextDecade’s ability to secure additional debt and equity financing in the future to complete the Terminal; the accuracy of estimated costs for the Terminal; statements that the Terminal, when completed, will have certain characteristics, including amounts of liquefaction capacities; the development risks, operational hazards, regulatory approvals applicable to the Terminal’s and the third-party pipeline’s construction and operations activities; NextDecade’s anticipated competitive advantage and technological innovation which may render its anticipated competitive advantage obsolete; the global demand for and price of natural gas (versus the price of imported LNG); the availability of LNG vessels worldwide; changes in legislation and regulations relating to the LNG industry, including environmental laws and regulations that impose significant compliance costs and liabilities; the 2019 novel coronavirus pandemic and its impact on NextDecade’s business and operating results, including any disruptions in NextDecade’s operations or development of the Terminal and the health and safety of NextDecade’s employees, and on NextDecade’s customers, the global economy and the demand for LNG; risks related to doing business in and having counterparties in foreign countries; NextDecade’s ability to maintain the listing of its securities on a securities exchange or quotation medium; changes adversely affecting the business in which NextDecade is engaged; management of growth; general economic conditions; NextDecade’s ability to generate cash; compliance with environmental laws and regulations; the result of future financing efforts and applications for customary tax incentives; and other matters discussed in the “Risk Factors” section of NextDecade’s Annual Report on Form 10-K for the year ended December 31, 2019 and other subsequent reports filed with the Securities and Exchange Commission, all of which are incorporated herein by reference.

Additionally, any development of the Terminal remains contingent upon completing required commercial agreements, acquiring all necessary permits and approval, securing all financing commitments and potential tax incentives, achieving other customary conditions and making a final investment decision to proceed. The forward-looking statements in this press release speak as of the date of this release. Although NextDecade believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that the expectations will prove to be correct. NextDecade may from time to time voluntarily update its prior forward-looking statements, however, it disclaims any commitment to do so except as required by securities laws.

Patrick Hughes

[email protected]

+1 (832) 209-8131

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Energy Other Energy Environment Oil/Gas

MEDIA:

Logo
Logo
Posted on

Viant Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Conference Call

IRVINE, Calif., March 08, 2021 (GLOBE NEWSWIRE) — Viant Technology Inc. (NASDAQ:DSP) today announced it will release its fourth quarter and full year 2020 financial results after U.S. markets close on Monday, March 22, 2021. Viant will host a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the business and financial performance.

Fourth Quarter and Full Year 2020 Results and Conference Call
   
Date: Monday, March 22, 2021
   
Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time
   
Webcast: https://investors.viantinc.com

Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.viantinc.com.

About Viant

Viant® is a leading people-based advertising software company that enables marketers and their agencies to centralize the planning, buying and measurement of their advertising investments across most channels. Viant’s self-service Demand Side Platform (DSP), Adelphic®, is an enterprise software platform enabling marketers to execute programmatic advertising campaigns across Connected TV, Linear TV, mobile, desktop, audio and digital out-of-home channels. Viant’s Identity Resolution capabilities have linked 115 million U.S. households to more than 1 billion connected devices and is combined with access to more than 280,000 audience attributes from more than 70 people-based data partners. Viant is an Advertising Age 2021 Best Places to Work award winner and Adelphic is featured on AdExchanger’s 2021 Programmatic Power Players list. To learn more, visit viantinc.com and adelphic.com or follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Press Contact:
Jon Schulz
[email protected]
313.850.4803

Investor Contact:
The Blueshirt Group
Nicole Borsje
Maili Bergman
[email protected]



Posted on

Gritstone Announces Promotions Within its Leadership Team

EMERYVILLE, Calif., March 08, 2021 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced two promotions within its leadership team. Karin Jooss, Ph.D., previously the company’s executive vice president of research and chief scientific officer, has been appointed to the position of head of research and development. Erin Jones, M.S., who served as the company’s executive vice president of global regulatory affairs and quality, has been appointed to the position of chief operating officer (COO).

“We have multiplied the number of programs underway at Gritstone, and the launch of our new infectious disease pipeline in addition to our robust clinical oncology programs has required intense efforts across the company, but in particular within research and biomanufacturing,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone. “I am thrilled to have had the right strategic leaders within the company to step into these important roles as we embark on the next exciting chapter in Gritstone’s evolution.”

Dr. Allen continued, “Karin Jooss has led the research organization to establish compelling pre-clinical data with our technologies against COVID-19 and HIV infections. Her thought partnership in the overall design of these programs encompassed efficient proof-of-concept clinical trials intended to address real-world patient needs. Erin Jones is a seasoned executive who has already been running many critical operating functions, including regulatory affairs, the entire quality organization (a major component of biomanufacturing) and project leadership. In the newly created position of COO, he will oversee all biomanufacturing, in addition to his current roles.”

Karin Jooss, Ph.D., is the head of research and development. She had most recently served as the executive vice president of research and chief scientific officer at Gritstone since April 2016. Prior to Gritstone, from May 2009 to April 2016, Dr. Jooss was the head of cancer immuno-therapeutics in the vaccine immuno-therapeutics department at Pfizer, Inc., a public pharmaceutical company, where she was also a member of the vaccine immuno-therapeutics leadership team and served as head of the immuno-pharmacology team with responsibilities including clinical development. Prior to joining Pfizer, Dr. Jooss served as vice president of research at Cell Genesys, Inc., from June 2005 to April 2009, and as senior director of research at Cell Genesys from July 2001 to June 2005. She is on the editorial board of Molecular Therapy and the Journal of Gene Medicine and is a member of the Immunology and Educational Committee of the American Society of Gene & Cell Therapy and the Industry Task Force of the Society for Immunotherapy of Cancer. Dr. Jooss serves on the board of directors of Fate Therapeutics, Inc. Dr. Jooss received her diploma in theoretical medicine from the University of Marburg in Germany, a Ph.D. in molecular biology from the University of Marburg in Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania.

Erin E. Jones, M.S., is the chief operating officer. He had served as Gritstone’s executive vice president of global regulatory affairs and quality since May 2016. Prior to Gritstone, from July 2014 to April 2016, Mr. Jones served as vice president, global head of regulatory affairs, medical writing, pharmacology and toxicology at Puma Biotechnology, Inc., or Puma, a public biopharmaceutical company. Prior to Puma, Mr. Jones served as director, regulatory affairs at BioMarin Pharmaceutical Inc. from July 2012 to July 2014. Earlier in his career, Mr. Jones held various positions at Genentech, Inc., or Genentech, a biotechnology corporation and subsidiary of Roche, including head of regulatory intelligence and leader of the HER Franchise Regulatory Group. Mr. Jones received a B.S. in microbiology and chemistry from the University of Pittsburgh and an M.S. in computer systems from Pennsylvania State University.

About Gritstone

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off the shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. The company also has a bispecific antibody (BiSAb) program for solid tumors in lead optimization. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine with support from departments within the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation and a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit gritstoneoncology.com.

Gritstone Forward-Looking
Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone’s therapeutic programs. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone’s most recent Quarterly Report on Form 10-Q filed on November 5, 2020 and any current and periodic reports filed with the Securities and Exchange Commission.


Gritstone Contacts


Media:
Dan Budwick
1AB
(973) 271-6085
[email protected]

Investors:
Alexandra Santos
Wheelhouse Life Science Advisors
(510) 871-6161
[email protected]



Posted on

Zix Sets Spring 2021 Conference Schedule

Zix Sets Spring 2021 Conference Schedule

DALLAS–(BUSINESS WIRE)–Zix Corporation (Zix) (NASDAQ: ZIXI), a leading provider of cloud email security, productivity, and compliance solutions, is scheduled to participate at the following virtual financial conferences in Spring 2021:

Stephens Best Ideas Virtual Conference

Fireside chat March 10, 2021 at 2:00 p.m. ET with one-on-one meetings March 10-11, 2021

Webcast

Wedbush Security Conference

Fireside chat Friday, March 12, 2021 at 10:00 a.m. ET

Lytham Partners Spring 2021 Investor Conference

Presentation and one-on-one meetings March 30-April 1, 2021

Webcast

To receive additional information or to schedule a one-on-one meeting, please contact Zix’s IR team at [email protected].

About Zix Corporation

Zix Corporation (Zix) is a leader in email security. Trusted by the nation’s most influential institutions in healthcare, finance, and government, Zix delivers a superior experience and easy-to-use solutions for email encryption and data loss prevention, advanced threat protection, unified information archiving and bring your own device (BYOD) mobile security. Focusing on the protection of business communication, Zix enables its customers to better secure data and meet compliance needs. Zix is publicly traded on the Nasdaq Global Market under the symbol ZIXI. For more information, visit www.zixcorp.com.

Zix Company Contact

Geoff Bibby

1-214-370-2241

[email protected]

Zix Investor Contact

Matt Glover and Tom Colton

Gateway Investor Relations

1-949-574-3860

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Internet Security Mobile/Wireless Technology Software

MEDIA:

Logo
Logo